Literature DB >> 33513800

High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes.

Md Salman Shakil1, Shahida Parveen2,3, Zohaib Rana1, Fearghal Walsh2, Sanam Movassaghi2, Tilo Söhnel2, Mayur Azam1, Muhammad Ashraf Shaheen3, Stephen M F Jamieson4, Muhammad Hanif2, Rhonda J Rosengren1, Christian G Hartinger2.   

Abstract

Hydroxypyr(id)ones are a pharmaceutically important class of compounds that have shown potential in diverse areas of drug discovery. We investigated the 3-hydroxy-4-pyridones 1a-1c and 3-hydroxy-4-thiopyridones 1d-1f as well as their Ru(η6-p-cymene)Cl complexes 2a-2f, and report here the molecular structures of 1b and 1d as determined by X-ray diffraction analysis. Detailed cell biological investigations revealed potent cytotoxic activity, in particular of the 3-hydroxy-4-thiopyridones 1d-1f, while the Ru complexes of both compound types were less potent, despite still showing antiproliferative activity in the low μM range. The compounds did not modulate the cell cycle distribution of cancer cells but were cytostatic in A549 and cytotoxic in NCI-H522 non-small lung cancer cells, among other effects on cancer cells.

Entities:  

Keywords:  3-hydroxy-4-pyridone; 3-hydroxy-4-thiopyridone; Ru(arene) complexes; anticancer agents; apoptosis; cytotoxicity

Year:  2021        PMID: 33513800     DOI: 10.3390/biomedicines9020123

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  2 in total

1.  Ru(ii)arene(N^N bpy/phen)-based RAPTA complexes for in vitro anti-tumour activity in human glioblastoma cancer cell lines and in vivo toxicity studies in a zebrafish model.

Authors:  Anuja P K; Binoy Kar; Nilmadhab Roy; Priyankar Paira
Journal:  RSC Adv       Date:  2022-06-29       Impact factor: 4.036

Review 2.  Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies.

Authors:  Md Salman Shakil; Mahruba Sultana Niloy; Kazi Mustafa Mahmud; Mohammad Amjad Kamal; Md Asiful Islam
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.